[HTML][HTML] Current status and prospects of targeted therapy for osteosarcoma

Z Hu, S Wen, Z Huo, Q Wang, J Zhao, Z Wang, Y Chen… - Cells, 2022 - mdpi.com
Osteosarcoma (OS) is a highly malignant tumor occurring in bone tissue with a high
propensity to metastasize, and its underlying mechanisms remain largely elusive. The OS …

[HTML][HTML] Osteosarcoma: current concepts and evolutions in management principles

P Pilavaki, A Gahanbani Ardakani, P Gikas… - Journal of Clinical …, 2023 - mdpi.com
Osteosarcoma is a rare malignancy arising from mesenchymal tissue, and represents the
most common bone sarcoma. The management of osteosarcoma is challenging, and …

Targeted therapy for osteosarcoma: a review

S Li, H Zhang, J Liu, G Shang - Journal of cancer research and clinical …, 2023 - Springer
Background Osteosarcoma is a common primary malignant tumour of the bone that usually
occurs in children and adolescents. It is characterised by difficult treatment, recurrence and …

Current and future therapeutic approaches for osteosarcoma

DJ Harrison, DS Geller, JD Gill, VO Lewis… - Expert review of …, 2018 - Taylor & Francis
Introduction: Current treatment of osteosarcoma includes surgical resection of all gross
disease in conjunction with systemic chemotherapy to control micro-metastatic disease. This …

Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies

F Lamoureux, V Trichet, C Chipoy… - Expert review of …, 2007 - Taylor & Francis
Osteosarcoma is the most frequent primary bone tumor and occurs mainly in young patients
(average age: 18 years). No evolution of the survival rates has been recorded for two …

The current and future therapies for human osteosarcoma

JD Lamplot, S Denduluri, J Qin, R Li… - Current cancer …, 2013 - ingentaconnect.com
Osteosarcoma (OS) is the most common non-hematologic malignant tumor of bone in adults
and children. As sarcomas are more common in adolescents and young adults than most …

Advancing therapy for osteosarcoma

J Gill, R Gorlick - Nature reviews Clinical oncology, 2021 - nature.com
Improving the survival of patients with osteosarcoma has long proved challenging, although
the treatment of this disease is on the precipice of advancement. The increasing feasibility of …

[HTML][HTML] Future directions in the treatment of osteosarcoma

A Smrke, PM Anderson, A Gulia, S Gennatas… - Cells, 2021 - mdpi.com
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–
3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate …

Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs

C Chen, L Xie, T Ren, Y Huang, J Xu, W Guo - Cancer letters, 2021 - Elsevier
Osteosarcoma (OS) is the most common primary malignancy of the bone and has a high
propensity for local invasion and metastasis. Although combining surgery with …

[HTML][HTML] Novel immunotherapies for osteosarcoma

Y Lu, J Zhang, Y Chen, Y Kang, Z Liao, Y He… - Frontiers in …, 2022 - frontiersin.org
Osteosarcoma (OS) is the most common primary malignant bone sarcoma mainly affecting
adolescents and young adults, which often progresses to pulmonary metastasis and leads to …